palliative-clinical-trials-2019-scientifictracks

23 / 23

Page 62
Notes:
allied
academies
February 28-March 01, 2019 | Paris, France
Palliative Care, Obstetrics and Gynecology Stroke and Clinical Trials
International Conference on
Joint Event on
International Conference on
&
Journal of Research and Reports in Gynecology and Obstetrics | Volume: 3
Using alternative medicine NurAid II in the treatment of acute phase of stroke
Genc Struga
University Hospital Mother Teresa, Albania
NurAiD II contains 9 natural herbal extracts with proven
effect to stimulate neuroplasticity and improve morbidity
and cognition particularly in patients with ischemic stroke.
The effect is in proliferation, differentiation and the migration
of neuronal cells and the formation of new neuronal circuits
affecting recovery of patients after stroke.
The activation by NeuroAid of the ATP sensitive potassium
channel located in the suffering neurons of the brain protects
them fromdeath. Indeed, the opening of the channel decreases
the excitability of neurons (by hyperpolarization) preventing
an overload of calcium and release of excitotoxic glutamate.
Besides the beneficial effects in neuroplasticity already
published, these results strengthen the interest of NeuroAid in
stroke recovery. NurAid II prevents necrosis and apoptotic cell
death induced by global ischemia, enhances neurogenesis, and
enhances functional recovery. This makes MLC901a potential
novel therapeutic strategy in treating cognitive and neurological
deficits caused by global ischemia from conditions that deprive
the brain of oxygen and glucose, such as cardiac arrest.
Data from the Chinese MedicineNeuroaid Efficacy on Stroke
recovery (CHIMES) study, an international,randomized,
placebo-controlled, double-blind trial investigating the efficacy
of MLC601 on stroke recovery in patients with ischemic stroke
of intermediate severity in the preceding 72 hours showed
improve long term morbidity and cognition. Functional
independence defined as mRS ≤ 1 was significantly increased at
6 months and persisted up to 18 months after a stroke.
The results of the studies confirmed the overall benefit of
NeuroAiD in stroke recovery and showed that treatment effect
for achieving functional independence was greater among non-
acute strokes, consistent with previous studies. In addition, the
study showed that NeuroAiD had an excellent safety profile.
Speaker Biography
Genc Struga is a Consultant Neurologist and Stroke in University Hospital Mother
Teresa and attending Physician at Cerebrovascular Intensive Care Unit. He is an
Experienced Consultant with a demonstrated history of working in the hospital
& health care industry. Skilled in Clinical Research, Medical Education, Medicine,
Neurology&Stroke, Neurosonology and Clinical Trials. Strong consulting professional
with a Doctor of Philosophy (Ph.D.) focused in Neuroscience from University of Tirana
Faculty of Medicine.
e:
Genc Struga, Res Rep Gynaecol Obstet, Volume 3
DOI: 10.4066/2591-7366-C1-002